0001564590-22-029511.txt : 20220815 0001564590-22-029511.hdr.sgml : 20220815 20220815174909 ACCESSION NUMBER: 0001564590-22-029511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220815 DATE AS OF CHANGE: 20220815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Medical Systems, Inc. CENTRAL INDEX KEY: 0001716621 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 383661826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38677 FILM NUMBER: 221167169 BUSINESS ADDRESS: STREET 1: 2070 LAS PALMAS DRIVE CITY: CARLSBAD STATE: CA ZIP: 92011 BUSINESS PHONE: (760) 804-1648 MAIL ADDRESS: STREET 1: 2070 LAS PALMAS DRIVE CITY: CARLSBAD STATE: CA ZIP: 92011 8-K 1 rmed-8k_20220815.htm 8-K rmed-8k_20220815.htm
false 0001716621 0001716621 2022-08-15 2022-08-15

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

 

August 15, 2022

 

Ra Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-38677

 

38-3661826

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

2070 Las Palmas Drive

Carlsbad, California 92011

(Address of principal executive offices, including zip code)

 

(760) 804-1648

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RMED

 

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On August 15, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2022. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated August 15, 2022.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

RA MEDICAL SYSTEMS, INC.

 

 

 

 

 

Date: August 15, 2022

 

By:

 

/s/ Brian Conn

 

 

 

 

Brian Conn

 

 

 

 

Chief Financial Officer

 

 

 

 

(Principal Financial and Accounting Officer)

 

 EX-99.1 2 rmed-ex991_36.htm EX-99.1 rmed-ex991_36.htm

Exhibit 99.1

 

 

Ra Medical Systems Reports Second Quarter 2022 Financial Results

 

CARLSBAD, Calif. (August 15, 2022) – Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) reports financial results for the three and six months ended June 30, 2022 and provides a business update.

 

“We are continuing to pursue a potential merger with a privately held company, Catheter Precision, Inc. (“Catheter Precision”), which would give our shareholders exposure to Catheter Precision’s innovative medical devices to improve the treatment of cardiac arrhythmias while allowing the combined company to explore funding for the Catheter Precision devices through the public capital markets,” said Ra Medical CEO Will McGuire. “Although consummating the merger with Catheter Precision is our priority, our board of directors continues to review other strategic alternatives that could result in changes to our business strategy and future operations, with a goal of maximizing shareholder value.”

 

On July 22, 2022, the Company disclosed the signing on June 18, 2022 of a non-binding summary of proposed terms (the “Term Sheet”) to acquire 100% of the outstanding equity interests of Catheter Precision (the “Merger”).

Ra Medical cannot provide any commitment as to the timing of a determination or the strategy the Company may adopt if the Company is unable to consummate the Merger and may be required to dissolve the Company or pursue other strategic transactions. Because of the significant uncertainty regarding Ra Medical’s future plans, the Company is not able to accurately predict the impact of a potential change in its business strategy and future funding requirements. The Merger is also subject to specified conditions precedent that must be satisfied or waived, including certain conditions precedent that are subject to the approval or consent of third parties. The Company cannot assure that all of the conditions precedent will be satisfied or waived or that it will receive any of the required third party consents or approvals or able to satisfy or waive all the conditions precedent to consummate the Merger. If the conditions precedent are not satisfied or waived in a timely manner or at all, the Merger may not occur or may be delayed, and the Company may lose some or all of the intended benefits of the proposed Merger with Catheter Precision.

 

Additional information regarding the Ra Medical non-binding Term Sheet with Catheter Precision is available in a Form 8-K filed on July 22, 2022 with the Securities and Exchange Commission (the “SEC”).

 

Second Quarter Financial Highlights

 

Revenues for the second quarter of 2022 consisted of product sales of $5,000, compared with product sales of $9,000 for the second quarter of 2021.  

 

Cost of revenues for the second quarter of 2022 was $66,000, compared with $0.5 million for the second quarter of 2021.

 

Selling, general and administrative expenses (SG&A) for the second quarter of 2022 were $2.5 million, which included $0.1 million in stock-based compensation, compared with $3.4 million for the second quarter of 2021, which included $0.5 million in stock-based compensation. Research and development (R&D) expenses for the second quarter of 2022 were $2.4 million, which included $19,000 in stock-based compensation, compared with $2.8 million for the second quarter of 2021, which included $0.1 million in stock-based compensation.

 

During the second quarter of 2022, the Company recorded restructuring and impairment charges of $3.5 million for expenses related to the reduction in force, impairment of property and equipment, inventory obsolescence charges and the write-off of R&D supplies in June 2022. There were no comparable charges in the prior-year period.

 

The loss from continuing operations for the second quarter of 2022 was $8.4 million, or $0.26 per share on 32.2 million weighted-average shares outstanding. This compared with a loss from continuing operations for the second

quarter of 2021 of $4.7 million, or $1.15 per share on 4.1 million weighted-average shares outstanding. Loss from discontinued operations for the second quarter of 2021 was $0.5 million. There was no comparable charge in the second quarter of 2022.

 

Adjusted EBITDA for the second quarter of 2022 was negative $4.7 million, compared with negative $5.8 million for the second quarter of 2021. Adjusted EBITDA is a non-GAAP measure presented as loss from continuing operations before depreciation and amortization expense, interest income, interest expense, income tax expense, stock-based compensation, gain on extinguishment of promissory note, restructuring and impairment charges and loss (gain) on sales and disposals of property and equipment. For additional information regarding the non-GAAP financial measures discussed in this news release, please see "Non-GAAP Reconciliations" below.

 

Six Month Financial Highlights

 

Revenues for the first six months of 2022 consisted of product sales of $14,000, compared with product sales for the first six months of 2021 of $13,000.

 

Cost of revenues for the first six months of 2022 was $0.2 million, compared with $1.0 million for the first six months of 2021.

 

SG&A expenses for the first six months of 2022 were $4.8 million, which included $0.2 million in stock-based compensation, compared with $7.1 million for the first six months of 2021, which included $1.5 million in stock-based compensation. R&D expenses for the first six months of 2022 were $5.5 million, which included $68,000 in stock-based compensation, compared with $5.6 million for the first six months of 2021, which included $0.2 million in stock-based compensation.

 

For the six months ended June 30, 2022, the Company recorded restructuring and impairment charges of $3.5 million for expenses related to the reduction in force, impairment of property and equipment, inventory obsolescence charges and the write-off of R&D supplies in June 2022. There were no comparable charges in the prior-year period.

 

The loss from continuing operations for the first six months of 2022 was $13.9 million, or $0.53 per share on 26.1 million weighted-average shares outstanding, compared with a loss from continuing operations for the first six months of 2021 of $11.6 million, or $3.31 per share on 3.5 million weighted-average shares outstanding.

 

Adjusted EBITDA for the first six months of 2022 was negative $9.8 million, compared with negative $11.8 million for the first six months of 2021.

 

Ra Medical reported cash and cash equivalents of $11.1 million as of June 30, 2022.

 

Non-GAAP Financial Measures

 

Ra Medical has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and six month periods ended June 30, 2022 and 2021. EBITDA and Adjusted EBITDA are performance measures that provide supplemental information management believes is useful to analysts and investors to evaluate Ra Medical’s ongoing results of operations, when considered alongside other GAAP measures. These measures are intended to aid investors in better understanding Ra Medical’s current financial performance and prospects for the future as seen through management. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Management believes that these non-GAAP financial measures facilitate comparisons with Ra Medical’s historical results and with the results of peer companies who present similar measures (although other companies may define non-GAAP measures differently than we define them, even when similar terms are used to identify such measures). Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Ra Medical encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP operating results are presented in the accompanying tables of this news release.

 

2

 

 

Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Ra Medical defines EBITDA as our GAAP loss from continuing operations as adjusted to exclude depreciation and amortization, interest income, interest expense and income tax expense. Ra Medical defines Adjusted EBITDA as EBITDA adjusted to exclude stock-based compensation, gain on extinguishment of promissory note, restructuring and impairment charges and loss (gain) on sales and disposals of property and equipment.

 

About Ra Medical Systems

 

Ra Medical Systems, Inc. is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System is used as a tool in the treatment of peripheral artery disease.

 

Cautionary Note Regarding Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements concerning the proposed Merger with Catheter Precision, Ra Medical’s future financial performance and Ra Medical’s ability to conserve capital and maximize any strategic opportunity. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the risk that the proposed Merger may not be completed in a timely manner or at all, which may adversely affect the price of the Company’s securities; (ii) the outcome of any legal proceedings that may be instituted against the Company, Catheter Precision, the combined company following the Merger, if consummated, or others following an announcement of the merger agreement, if entered into, relating to the proposed Merger, any ancillary agreements contemplated thereby and the transactions contemplated thereby; (iii) the inability to issue to obtain any necessary stockholder approvals for the Merger, any securities issued in connection therewith, or any transactions contemplated thereby; (iv) the Company’s inability to satisfy or have waived the conditions precedent to the closing of the Merger; (v) changes to the structure of the proposed Merger that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed Merger; (vi) the ability to meet stock exchange listing standards following the consummation of the proposed Merger, if effected; (vii) the risk that the proposed Merger transaction disrupts current plans and operations of the Company or diverts management’s attention from the Company’s ongoing business operations and potential difficulties in the Company’s operations as a result of the announcement and consummation of the proposed Merger; (viii) the ability to recognize the anticipated benefits of the proposed Merger, if consummated; (ix) costs related to the proposed Merger, if consummated; (x) changes in applicable laws or regulations; (xi) the possibility that the Company or the combined company following the Merger, if consummated, may be adversely affected by other economic, business, regulatory, and/or competitive factors; (xii) the combined company’s estimates following the Merger, if consummated, of expenses and profitability; (xiii) the evolution of the markets in which the combined company following the Merger, if consummated, would compete; (xiv) the ability of the Company or the combined company following the Merger, if consummated, to implement its strategic initiatives and continue to innovate its existing products; (xv) the ability of the combined company following the Merger, if consummated, to defend its intellectual property and satisfy regulatory requirements; (xvi) the ability of the Company or the combined company following the Merger, if consummated, to issue equity or equity-linked securities in connection with the proposed Merger or in the future; (xvi) the impact of the COVID-19 pandemic on the Company’s or the combined company’s business following the Merger, if consummated; and (xvii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s prospectus, dated February 4, 2022 and prospectus supplement dated July 22, 2022 relating to its public offering of units and other documents filed and to be filed by the Company with the SEC, and in the Company’s Current Report on Form 8-K filed on July 22, 2022, and other information affecting Ra Medical’s business and operating

3

 

results is contained in Ra Medical’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and in its other filings with the Securities and Exchange Commission. Additional information is also set forth in Ra Medical’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 24, 2022, and as amended on July 13, 2022. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

 

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company and Catheter Precision assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither the Company nor Catheter Precision gives any assurance that either the Company or Catheter Precision will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by the Company or Catheter Precision or any other person that the events or circumstances described in such statement are material.

 

Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

 

Disclaimer

 

This Current Report relates to a proposed business combination between the Company and Catheter Precision. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

 

Contact:

 

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com


4

 

 

Ra Medical Systems, Inc.

Condensed Balance Sheets

(Unaudited)

(in thousands, except par value data)

 

 

June 30,

2022

 

 

December 31,

2021

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

11,128

 

 

$

15,045

 

Accounts receivable, net

 

 

17

 

 

 

21

 

Inventories

 

 

43

 

 

 

986

 

Prepaid expenses and other current assets

 

 

1,144

 

 

 

1,037

 

Total current assets

 

 

12,332

 

 

 

17,089

 

Property and equipment, net

 

 

38

 

 

 

1,809

 

Operating lease right-of-use assets

 

 

1,967

 

 

 

2,110

 

Other long-term assets

 

 

36

 

 

 

36

 

TOTAL ASSETS

 

$

14,373

 

 

$

21,044

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

487

 

 

$

988

 

Accrued expenses

 

 

1,970

 

 

 

4,119

 

Current portion of operating lease liability

 

 

297

 

 

 

283

 

Total current liabilities

 

 

2,754

 

 

 

5,390

 

Operating lease liability

 

 

1,828

 

 

 

1,981

 

Total liabilities

 

 

4,582

 

 

 

7,371

 

Stockholders’ Equity

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 300,000 shares authorized; 32,279 and 7,010 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

 

 

10

 

 

 

8

 

Additional paid-in capital

 

 

201,996

 

 

 

191,937

 

Accumulated deficit

 

 

(192,215

)

 

 

(178,272

)

Total stockholders’ equity

 

 

9,791

 

 

 

13,673

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

14,373

 

 

$

21,044

 

 

 


5

 

 

RA MEDICAL SYSTEMS, INC.

Condensed Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

 

Three Months Ended

June 30,

 

 

Six Months Ended June 30,

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

$

5

 

 

$

9

 

 

$

14

 

 

$

13

 

Cost of revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

11

 

 

 

344

 

 

 

42

 

 

 

608

 

Service and other

 

55

 

 

 

176

 

 

 

119

 

 

 

359

 

Total cost of revenues

 

66

 

 

 

520

 

 

 

161

 

 

 

967

 

Gross loss

 

(61

)

 

 

(511

)

 

 

(147

)

 

 

(954

)

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

2,476

 

 

 

3,398

 

 

 

4,778

 

 

 

7,075

 

Research and development

 

2,396

 

 

 

2,829

 

 

 

5,511

 

 

 

5,579

 

Restructuring and impairment

 

3,527

 

 

 

—

 

 

 

3,527

 

 

 

—

 

Total operating expenses

 

8,399

 

 

 

6,227

 

 

 

13,816

 

 

 

12,654

 

Operating loss

 

(8,460

)

 

 

(6,738

)

 

 

(13,963

)

 

 

(13,608

)

Other income, net

 

12

 

 

 

2,019

 

 

 

20

 

 

 

2,012

 

Loss from continuing operations before income taxes

 

(8,448

)

 

 

(4,719

)

 

 

(13,943

)

 

 

(11,596

)

Income taxes

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Loss from continuing operations

 

(8,448

)

 

 

(4,719

)

 

 

(13,943

)

 

 

(11,596

)

Discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from discontinued operations before income taxes

 

—

 

 

 

(530

)

 

 

—

 

 

 

(889

)

Income taxes

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Loss from discontinued operations

 

—

 

 

 

(530

)

 

 

—

 

 

 

(889

)

Net loss

$

(8,448

)

 

$

(5,249

)

 

$

(13,943

)

 

$

(12,485

)

Net loss per share, basic and diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

$

(0.26

)

 

$

(1.15

)

 

$

(0.53

)

 

$

(3.31

)

Discontinued operations

 

—

 

 

 

(0.13

)

 

 

—

 

 

 

(0.25

)

Total net loss per share, basic and diluted

$

(0.26

)

 

$

(1.28

)

 

$

(0.53

)

 

$

(3.56

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares used in computing net loss per share, basic and diluted

 

32,162

 

 

 

4,089

 

 

 

26,133

 

 

 

3,506

 

 


6

 

 

Ra Medical Systems, Inc.

Non-GAAP Reconciliations

(Unaudited)

(in thousands)

 

 

Three Months Ended June 30,

 

 

 

Six Months Ended June 30,

 

Statements of Operations Data:

2022

 

 

2021

 

 

 

2022

 

 

2021

 

Loss from continuing operations

$

(8,448

)

 

$

(4,719

)

 

 

$

(13,943

)

 

$

(11,596

)

Depreciation and amortization

 

136

 

 

 

321

 

 

 

 

322

 

 

 

655

 

Interest income

 

(16

)

 

 

(18

)

 

 

 

(17

)

 

 

(19

)

Interest expense

 

—

 

 

 

(1

)

 

 

 

—

 

 

 

7

 

EBITDA

 

(8,328

)

 

 

(4,417

)

 

 

 

(13,638

)

 

 

(10,953

)

Stock-based compensation

 

123

 

 

 

625

 

 

 

 

285

 

 

 

1,697

 

Restructuring and impairment

 

3,527

 

 

 

—

 

 

 

 

3,527

 

 

 

—

 

Loss (gain) on sales and disposals of property and equipment

 

8

 

 

 

8

 

 

 

 

44

 

 

 

(493

)

Gain on extinguishment of promissory note

 

—

 

 

 

(2,023

)

 

 

 

—

 

 

 

(2,023

)

Adjusted EBITDA

$

(4,670

)

 

$

(5,807

)

 

 

$

(9,782

)

 

$

(11,772

)

 

 

#  #  #

7

 

 GRAPHIC 3 g3ttign00cfu000001.jpg GRAPHIC begin 644 g3ttign00cfu000001.jpg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end EX-101.SCH 4 rmed-20220815.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 rmed-20220815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 rmed-20220815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2022
Entity Registrant Name Ra Medical Systems, Inc.
Entity Central Index Key 0001716621
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-38677
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 38-3661826
Entity Address, Address Line One 2070 Las Palmas Drive
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92011
City Area Code 760
Local Phone Number 804-1648
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol RMED
Security Exchange Name NYSEAMER
XML 8 rmed-8k_20220815_htm.xml IDEA: XBRL DOCUMENT 0001716621 2022-08-15 2022-08-15 false 0001716621 8-K 2022-08-15 Ra Medical Systems, Inc. DE 001-38677 38-3661826 2070 Las Palmas Drive Carlsbad CA 92011 760 804-1648 false true false false Common Stock, par value $0.0001 per share RMED NYSEAMER true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports rmed-8k_20220815.htm rmed-20220815.xsd rmed-20220815_lab.xml rmed-20220815_pre.xml rmed-ex991_36.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rmed-8k_20220815.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "rmed-8k_20220815.htm" ] }, "labelLink": { "local": [ "rmed-20220815_lab.xml" ] }, "presentationLink": { "local": [ "rmed-20220815_pre.xml" ] }, "schema": { "local": [ "rmed-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmed", "nsuri": "http://www.ramed.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rmed-8k_20220815.htm", "contextRef": "C_0001716621_20220815_20220815", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rmed-8k_20220815.htm", "contextRef": "C_0001716621_20220815_20220815", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001564590-22-029511-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-029511-xbrl.zip M4$L#!!0 ( "2.#U6+&T>EL 0 /85 1 MEH32WOOK7W^Y_,WST/3F]C/Z0!1]A"F5A"4R$_#F[M-;]/6/^0S=D0=88S1- M2+8&KI"''I1*)T'P]/3DQTO*9<(RI55)GR3K 'F>$_RG &P(:(H5(/N;H'[8 M[WOAA1?U[_OAY&PT&0S]T?AB,!J?_1Z&DS"L"/@GMP%5?A,T]$,_\L_/SBN, M7S#YCE> ;J<5QL491,-X.!B,X.*,D.'B8@1#,CJ/QH1$@RBN(DW2K:"K!X7> MD+<6HK:7")S MS^EH<#F)@5[U"L]M%H+Y$HB_2AX#30B,QE[!J .DMBG(DGN)Y<)/Q"IPE!J[ M5*EH%FPH=5:A#HDN2?4#E!P034F-4:PA+CE-7@BL=VP^&+;P(AHZ5B,G5G6Q M!D$_#(=!3G2LL1)[>(WH\H0F!X9L5(1>&'G]J&)IHXTUT,"S=;\)2#\,8*. M2[I@X!DV$#:1I=Q+2ZHQ&S)MMEE[:1#HDE,Z M(\'QDR3C2FR;Q1?$F@)&^?!Q8:@DE$T+WFD-8 M"FH]#!ORT,QN* 4K5DK01:;@)A'K*2QQQG2$,_YOAAE=4HAUBV-@^E.-H4)6 M6*Q ?=9Y*5-,H&VVRKC)<.VF*/CZ:9;WQIXN>(1LR=-UF@B%\LJ?)<2FS1%7 MFR_/Q=,S6[HQ>H/(U\)ZB#>B/90,P0MAN+!W@K'+F L3/>D5[9 >KUGUXYN,HI.::[PJA6JSEUPD@ZL7>$86['[= MG=HQ,QKN%OLM6U5$X\W4T0%E$[2K]BZH-,]N%[(3=Z.^78+1".:STC!EW E85\ I U$M G-3+#HP1 M^;)]IE0'D([*W3QH%NT5[Z;($]4^&^D"8$K:(?:8\H9)\/44FP >=WIMV+;L MKP["MJCV(*H3?]?(NT>&79T0^]WCI*OYU3D[=T&QT\X!]3']54&VTU3RI=)L:4WS?PW,9;<:S&(ZJGY'M:ZQRN8V>>! M(?T]O_W)V)VWP?K)TYXL)2*'*88EY=3B#\T/>=5_93A5R.BZ#/9/[ O+),1_ M\6N[3H5^\O/<-973!*:@'SP9='P$VV\%S M9Q55YO#,D&V4Y#N$62G:9.U53^IB8>7;XW\W5Z?"J>;N9T^SU5\J7"<;7U9C MR]I3>)/P9+W- ;HB<7\_\/@CU["VM[KNQ=I"ZME"GVOV;ZW8CQ5GU%"=Y1+S M&.7B4$7>:?7:N>JZ%WKW>KT,]KMLL5/MQOE6?D%<_P!02P,$% @ )(X/ M5?O;9]HU!P Y$L !4 !R;65D+3(P,C(P.#$U7VQA8BYX;6S-7%MOVS88 M?1^P_\!Y+RU66;XD:6PT+3(G&8RE21"[6[%A*&2)=HC2I$'*B?WO1^H22S8E MZT+7S$MDA3SGTSF'(JG8_O!I-GCSS]]^,6RP-7-\ Y(NYCR)8-O1I_?@J^_ M/]Z"6T2^3QP.P15UEW-(?&"!)]]?]&W[Y>6EZ4T1X10O?<'.FRZ=V\"R8N@! M@X[\ [AR? B"GS[HM#H=JW5NM3OC3JM_N?=L][);ZU6O]5* /P5 M7A9(_/3!:;/5;#??G[Q/-'QPW._.#(+A5:+AY 2V3[W3;O<,GI^X[NGD_ R> MNF?OVSW7;7?;7K)2NE@S-'ORP1OW;5"BN%Y"(,9P#6X0<8B+' Q&\96^ T/B M-L$EQN!1=N/@$7+(GJ'7C%"QT*V/8_&$1X0'+R\:"?56$X:;E,WL3JO5M>/6 MC:CY:J?]2S=HW>[U>G;PU]>F'*D:"MBV_?7S[ M4C?PJ$!=(+.%?&7%S2QY2MAK==O-%?<:0@T 0CT8Q? 13H'\_>5QF,G9LV4+ MF\"9"(YWZTP@%C4'$$\,3M7],&.I;K*.GJRC?2;K^%6%YJ\78CQP-%]@H8I= MN]0[Z.NM=AM0=\$/D"'J71/-(JMA#U/\R'>89M6S@'5?P%CTG;:Q OOET3'_GK@5AW, -_*/C' !G\&V/_=WS+U2K3 M3"&T6AQO.,;B\HHZG.Y3S> DAO[Q_;J-DO#'=U@I,LT2PA1!<2DMZ\7P4C!X MDN4&.[.B.=SJ5$VW%(C^)+[" XE__"BJA::96A@C*BZGIYZ[XNL.2SY;*7M[ MW.I<;UBGP YXPPQY@" *GB<=/[#Y5M"]*ADG^_9MM;#B.M;XCW"&Y%J"^'?. MO'"BU7WKK/#36 =;X&]H@.0Y?IIS7:#[%#)-<5Q=[./N!=.%E]@&ZAB#UW/( M9HC,_F#TQ7\:T/G"(25WVQD0=?*AA#S8P(S90$@'(CY3!FB^1;2@;H;:@>LY MH64(K,;B/L&1_)](./^5S+^B?RVU=_ .E_P5V'!%D[\QL<^VA1:1RT0+< WU M=43]!F%XMYQ/("L7\62_.KIN< X6:4D!0@Y3DJQ0G>:I8I+"N+RX.H(Z)"YE M"\J"?U2/?+$5&="E6!BM!]0KN5/8 U5'[%SH@R4\Q?H.!+R ,A!Q TEN2O2+ M^4A+BFJX9SC;KLBM8E;I&$AC9S7TQ)8"35'XKH\JM_],D#I&9( >;-@(/I F M-&R:V&<5+:R>L;;@NH[H&!*7GB=JY]&O6T1@N]QP4 +4T5P!>+!A$)&\BP_D MV_T@N"?&3!EY]M!"JAEI!5:YD#*A_4-B/Q"']VQ,7TBET">[:]!Y W?XP$LN MN4Z2;(:%76&**NK;:AEH@#KF@?3W^Z37F/)@F77/'AA]1L0MN6/(PM @]Q;F MX4/_NCN(*0U+?I91JO@KQ3/5%/5 ".VX+V*'QM'P0+GOX'_0HOSN68V@0?04 MXN''04@'!)]1^^-<@U1C0"&;F6:H\U_8AIKO%927QJ!3)N_I/A7?*9C T)_I M8!:5\(9$6*DRS5+"%$5Q.3'K!5%^U@8_/%%2\K'[;K]J\FWCZ ]EP ""F.> MIV2J3O-4,4EA7%[<>D']FR'?AV1 Y_,EB9[&\*)IS>A<35 EF/[<1C0@S7/\ M[.8;0?=J9)SHN)K>]>(\HABYR$=D]EDLN!ER<-$LJWI6TW0727^*-QP@)CE^ MA'/$I_G2F"4TKJ!QO=@^,"C'!Q3R!F^?EY^N8O?3:?&%0QY"-76S$?7'67!9 M;H(,A&P@H#M^L O80XN)9J85^-4%,"CO@M;H#SE?0E9_ "APM&B_@_L#!D/( M:?:8R/9-/3(R=#39HZQ14LJ>FLL;Z"[%>FK=[DS&R,>%GW'L]JLXXV[AZ ]_ M OH%+0[;R9O04QX_+QG2D_SI#%)YGA9LP$' ?JAPCIFCOQJFM%Z/J&%E^%; MG:KIEP(Y0$9#>!#B'S^::J%IIA;&B(K+Z:GGWGF]Y+M!]"IFF."XE=O+$K3B27QX5G4+A%RI]_!]02P,$% M @ )(X/563S);[[O H86A"IJ.!-P[4< Q&.A4_YI&G,E>DI M3*F!5.AQWV."DZ:Q)LKX_.G''^Y^,DUT_]AY1BT:2?!@\?41? M?^MW49?RUY&G"+H7>!X0'B(33<-PUK#MY7)I^6/*E6#S$%I7%A:!C4PS#MV6 MQ-,7T+T7$A2]&JCDE$JF8<_#K]Z$H,[]GN&H0MRJ7RV7:^2V@G%U=%LC55R[<>L8 MNV77WT$,;)&CY1['%./H4&"9T%50!U@THVE#1GUV!HSZZ !$*)&Z_'TWHK007P7H# M*[X=XL\6]Q]X2,-UAX^%#").S\'M0Z!O60*=SF4FH?YX&%GK[ \(FH@6^/%M0/!<0OR' M%9YZ?$*> >$A"TP7KI#QG\P;$=8T3OO:UX0WE)X6V,$Z& EV*:XW3E<%%.?L MED9#&K+,7"5^5X75DZ0M J@83'39=)2:$SG4Q2A?QF,B+X5Y/DZ>L/\]X/R@ MPI!$,0VAKIY ^"2,4A=W?8KG5:']!84%PJ-YF'.Z&6;4I>A..%\5H![[6&\* M3"ZO'./_:X*JPWW8PNF3FWA7WP?'_I<%Q1C/S@ZAY\D4.QY.]"NN^>'\CM!\PPB/LN MF(BD>W6/A,D!\"PD!!R)F343E1O;3'GH5QGO\/.A,H! M_"-E&;7SV"\'6 \KF&MQ134//1C:A)\-7II_'C #(B7R= M$6EZB!S MN%^D![KP$1F]3O)"//(.0> ?3*A"EKA89;%0KKO5>'%BZ9-)3UP M7V^'7(KOA/-5 ;:@ 5\W\LB\R:7 WCCEPM@0,&0E:N-SW0F96!#9&ND"P>'% M,[)#IT- ^\OUEL0'(3V)XW#P]6BM?KCSLK6P9YZ$>":>4K;3NK$402J6;6LB MC3@A8:'2-%S'<1W+<0PT@[K3*\2F43+07 $8,=.P]7(!TH 5C21^=Y/W29@1 M1EAD*!)9_I_I>%/7"1_E8O)Q0H 27JK%Y"5]X$AHN2DR+4?C?<)+O3N@IM#2G;_4GY!14D0\?TB1T%%2 CQ^C[2@I%U1W3SSU M3'@IJ.JF/:M.2"FHUG[OC$%"3D&U]OR)D82B@NKO\=F?'265@NKOFR-:"1]% MU=W4HW0)+?^!\M[91ZS *NU5G['=7-%O^MSIIW\ 4$L#!!0 ( "2.#U5S MAZWQ8Q$ .V/ 4 H;.0G=:,@" M10PR4&K4*I?O[^]-K\\#&?J1@G6DZ8;#,C&,=.*V8!0;R E5C.B_%G$LQS&L MAF$[-X[5JM9;E9I9;S8J]6;UORVK95F9"?X6;X!D_EJD9EJF;>Y7]S,=+ZG[ MG=XRTCW)=.Q5F5WS:I5*G36JKEOK->JLYM;W[:;KVA7;RT(:CB:"WPX4V7%W M-8BPWR!@OL\FY)0'-' Y]!F0[U\MQ8]I5#)F7FUE0 M>*+I@)NP&G8M[1I)0TU&3$Z[]ZGLZ7G3%CTDT_V6TE%A;VS(=99J)/+P2N:: MM^%=&5MR73TE9N#((02:R]B,8RS#L@W'GBXBU*(=3)OR4 E5V#7?B;L+(.=N MKF- N2N+N^JF7&$4:#$HA%Q M8Q[N(!HZ19SG6 "Y8H'D/9\9V(T)+=O2<%"Y))P+ZN)[CK#W%3V!W6PVR[IU MRE]*+!2)9AE:TXYS4^:%!YM[5$Z%A\NPZMC[R\0M[C&%6?(BB*&K7?[][-NU M.V!#:LS**!\O6L%&@4:UB5ISRCR@3*+A(RP/G0R-6.Y.QST^*#^ CU7Q@ >8 MRDK00/9#,=0$1)!KAN483CTSB0%2UI*,>OA_ MR!359L5@_XKXW9=2.PR VY1Q WLL$3?^]J6D@ G+>C0IXSC%E<_@ ^I!H_'] MCU3IF= 'FLMI^V$Y70FU_?E74/@!6$?%!+E#>^*8^W:BN'NA-SDZ]/@=D6KB MLR\EC\N13R=(0X9 _\QX+]%?]'?J>QX0A'!3TZ1\6_@%B M M#/,"7CK6,PIAX:U%.?WB9;'*LKUH?-8W=[WZ[7'7NZI>F'TE&?^I(=EG/K M/+9V-;MV)P#$3-JPN*!^-_#8^%4+EB1:/;20J;^4)!^.?!0V_6P@$")-XRF!Q])+FZEP18B46EE)K*&G5E4_ M1X?E_'X>\#"S\1@7,HS$ RJTB]!*\*_)]AC^];AT(-/T3)ZE#[F'C_L<>%P# MQ0KEN=W]-4_,V<'I2N6"I9*51D#WT)M9'O2E4.CX'4T]OEHZR4-;?@Q(Q((1 M:4L>F.S"Z;,$B5GT9W =,V8JO(=ED'/X#Y]&J;CW0@&-A@I'K9,P FM''-.I MC=3!B'KH/NL6"[X/J;CE@=$+E0J'V2=I!P0## =BLF7]?- 'P S)_\U:56@L M'?WE)[MN'1R61T?9Y?4@ZO/;H.7"0"8V6^>>H5O:ZH6^EUG8;D!WGRF8UI C MZL)V6@9XT_!4=^K3(?],Y(==ZQ]^M]>=]F]7W9MNYYH/]#$O?;901.N;B"@N7B^$[GTS[>G% MU1E9[#I86=NLJ[!EB_KS<_VF>]1(LM*N"1*3K3P)"SI:"=N]8J-0*+*3?F<4_$LF%6%W& <5 MNIEYNZT7XHO--<[F_/<\Q-@4\XMMD%-D@RZU^]^)CP9K&2,2ARV^E/A8M3P8 M/82Q X].)D!D%I2.CJ/;""AMU_9T-'AKN#8U7,X;J+'%;%29CX)YTQA2L!&(7=:688I502>2( MN1A,\ @/"%>2@%W!X-ON#R5'SZKDX\#$H:(8@8B1\*4$GKC+?#^A^O1[@@C] M/0=+BT8J3%'HAKY/1Y*UT@\'Y)Y[:@#\ ,#H<*S201'ED3M- Z!'.)I.&7>N M.$G?IS!SE@KX/8\9?/#>#!.L&^0V[#$WC#,@K0C@%A@57ZIZ&O.J!U1%*$;) M--<*S% [SLFT0V]S>X:A>XRP*382X1VNB0;MA/GT'FS;O&K"K6D-=5A6W@S] M8Q+.L( ]RP'/1>_5")D5E *0"UBV^C8L^X&8.4^YSZ!GCXEU$P.V46G4 M]_<_(Z>]D7+\0)S6G.>T&SKN)ND&5T^U"=M5&D:E7K<;3GT%OBLGANY]F3M- MI">$_Y[3F]/6"&,?H1HP0?X9"2[!T=5!D<.>(.4CPY#PT=PL48ED? M-X[2M.@+'6U>/'[ZEI$JVYHW<,>>)YB4R;]O8"+M]8R;8^U;Y!L:%N(23 M%]?E8L]ZB&L#.:%3P.DLM$N +8AY)AK""_W]\M/9Y\ZCI "U>B0/?DV9- M,(*%"V6&!>*D_Q"JQ]'BIR/!KYX'^!@_72 M1']5\I[")S@AQH%_H6T8?*6QG@3"]DF<1/:(1(M(?"K3W*GYB>+_]65$>V"P M5Z):>\#<[P2.]H2.P,$ 4X;'_5XX)CWFA_=(-6Q$VI*&\2OITC(\<83QE)C&D T:$!I.TK1_Z ML#B.0Z>'XYE4DAW)&/G* B; TG8#&!O%88ACTS%C<*<9^/>:-*F]Z-%XCGNN MV6W(R&]=@ZV$2__E%L;X5Q:=PRDO+X ,+D&'" _,":%>I83L9&KNKB6;<=RN+U-06C&=8_/_$PP+X>RZ4L66JLE,0! TUP]_0]86%F800>NJ#1^/B#Y MF)?,Q+S(3_$;66]79;1ZD''CEU#PG?WX?0MW0%R?2KE6&8)I.A,\KE?54+S)FFG7MYPB*(KG,X33W^\>8Y=H1ZY7BO,99*#JF-5'=OD)9. \ M>>%"*TN6.AM@5>\'')X\F-[-3@(S)@GQL0*&7[=,]]6."TZNMB=Q<":VT],F M:\VR$W E@4K7*G2_[Q&01"1"Q,B?+1,'DA%>VS$H+-A?5P^\%O<_2U'U*N9N M12Y\ZYV^'E_FJJ(2JQ@;CC7?9SOKG&SY;3O_QW6''&L(:+",-Q\[.O]"W>^W(H23.1[80M'ZZ53_+2=20=H^&9VP MP!N&)[H!OGJ*>?L)<75"'P#_#H:?Z9K]F6P[EX0&A 'B;C$! *BX5P.,:(PP M T\E\5B?!_$KFG$FSJJEA_*9-%Q\%4!E&LY =L_T$DYJ[:+52!Q-,3I&4[! M%$77"LS.A0$2'+YKSGKW/QX=.PMHDGO;9EF\=-G[-K7YZL]TO:]ZN7:\VNLD M Z=OXBP(:JU4Q55 N+=1D-W^$I'"FK9"^>1SA3 #D#[F,U>!] 6ACHU%DNE> M;)R6VR!$7,?+XEO/D 9Z+7^"B]]S6!JY)H#=0XM@=US"N/[T\EKJZAL_L3/> M9>E1X;S\&:]@#?'-].-QM<[O$[4O9 Q\R?+XMO@ MUBD^>_ZJLJ6S+KMF[EEA'8ATVA&]949/,/K=H'WP@%K4OZ<3F=S6^;35UW?W MGKSD6Y2*=A4; I-9CHEW2D>^TL7F%Z/TOET05Z39-&U4M&H '=KZYF:57C<$ M>G=:=HE0Z)K+]#U+F 9<.P8N&MB4Z;VBZY%>7RSUKFB/B.3!]"9A]$ U9J:B ML*%*V(#Q7N(9YZ#,G;CT3 I<8X$G$ VE];U1X#%Q>,M4=*?>XSKS0E M.=B^42B9%K2I[6NLZ+GN(6'I4'/(WO2-V7LPOD1&O7_"=#&E&?$Y[7$_GDG/ M356Z7,Q,13AP$^Z(*Z;SV\GQ198AL$HWU-Y ZF7H.?7[1#J1.7VQUTMO]= :\VO9\&;E32!XAMAP./PDY=G$+;; MI*@W]QHQ\6&="._R!PQ@+QFY@Z2<>(]$@9Y@QG]B8RUU6(+,8DF&7<#PS- 8 MV_I!#LL2B0.H!!]#@A\D,MP!.UF,8!6+X2+)TW+66#E#6RQ:*YJ=I]B9IFG9 M9O8'#E(.D5F)DT^S+6^;A\:K^])]/)\79-OO-;-<4"KB/)H.6AK&?_3"X\W2 M(O:+W@&6D#QW3IE_&?:L*)LYOSV=(6+F_X" SW#R!Z/)VKSW MHMO(F>>7ET?T^]\%@[ZRUGUE&JX4_MXXIT1)YM<\V+C9M/^HU/'G6M:X7>HR M=\;VM'<^$SPPIR$]NN'-3Z\A0%O=_.K\OE6]FXBM;57?!?MM->_FKWR'=TR0 M2_TKB5B<0/4//N)/,U*BK_S:8<,>\[PD"J3C3RSW"Y!IK"C.R;[\U5%%9^R/ MD&J8KP/9+&>]2E9B81+[97_EIOOU_/CFMZOY'_1Y;*?3 /3RP%@)=U:;9_& 7QUH?#N** MN=[+7F\/\-OY/H?US>=L^L]TCUO%[D36S%_ M'Q!OQ?QCB_GF(*\KB$]*A'S0"FG\W:'6;.AI/4[]"&C;3&M\A)T]-T/\,FEM MR9\HM(V3A1^4]F59)K_@0ZS)VS!CN/5IMC[-#X'CO KX%*^-;F7_ T"\E?W/ M<)YY;M%N#SCK9\HD+_0U[V(KY^\6XJVUZ/[=TX\5QB>T\JG[8H$K:X0Y$*2=GC_/JW&P I2I9D M^2(1!'N3FAE)O #=C>?I;@"-]_]S\N7XZM]?3]G?KCZ=LZ^_?SP_.V9;.[N[ M_^H<[^Z>7)W('_9:;9M=)6Z4!ED01VZXNWOZ>8MM#;)L]'9W]^[NKG77:<7) MS>[5Q>X@&X9[NV$$$_]N_A M[[^\'[$TNP_YAZVAF]P$T4X_SK)X^+8]RMZI;[)X)#YF_'NV$T0^C[*W[9_> M7<=1MG/M#H/P_NU5,.0I^\SOV$4\="/Y6QK\E[^U\4[Q\8X'-X/L;10G0S=4 M5^";\V_$XS,4V35\ =]&7%YUZR:!"^]DZL*M7]X'PQN6)MZ'K9M.E@4W4;OM M78_;^)_=^G-TL\6$1#YL;3$WS/ OU<>[P,\&;QVG/?K^;B#;TSV$?\,C=T>_ ME(0A&N.&\.BW"5[V[EG245WNQZ$_):XCZ% X5TC/EC=_-?D3_PX1M?_HJ20CQX"D]>22-2_DXN_SD*>J9&+ESVB?N! MYX;L\C[-^#!E%WP4)UG*+KD71S[[Y]@50]-I.P[[-8C[^+/OTS=(-KB@X83%Y'_[1AZFH1!WJ+91STT M$XN=1=XK/+DU[QESKV3;G_]]>HUWKK8 M\E^11Y4"_P6Z2#@#4,J":!Q$-RR+V6B@A/">#7CHP]W""BRVHLW"4'3!%A OR;<"U+X69A^JS"\AQ?D-J84;[&[ M0> -V%T\AA;.$I0/HS@"PA"=@5M]'<3J&[D&?YC_0[KY+61!%,70' M'S%4X]'GMX$'JH<;@R%:(9?&FW W&X)(6'S-/#?Q ]<#^26#^VPP#-P4VQ2" MX,(POA.R'*!HAWWH="$E?"8T+(RA7=<@$[PN'QP/&SEIR2")QS<#<=EHW \# M#QHP"C+4C9M\XUEJY4,T=0.?E<#E^/0+^U<0ANR3]]LX2'@K'[U'8380#P7U MI^/A$&2@&EU6]YQ&!:D0-IA!G 09*!X_]6,0" K&AW=X60P*4&8E!9E 3V D MQ? TT!-8:<9OH!?@I?$D$N+'7KH9W(4JE< !RF'>P(UNY#/$>W(D4,^X%U!Q M/A.##*!90_=[, S^BUTL60F[=<,Q;RG9Z0HG'UWOVPT8 M0.3O>#&8SML??A7_/;DYZNY.#_^W>=3Y$@'* VPXCD1Y2YJ]&AE^D'HA1$*^ M^#8% :"RXD@R@WVHF %TZ<(CH=>!'#["=I-[_ '&ZD@^@2?@=FV7N.H*OF&7 M \ZS@J[ HESO/S@FF-UN_X0/P!OB<99FKGPVAY^S>S!#>"!/@:HMP0ZX$Q$<98S.$/U @ . PF?KAC- E)A3**24:<^"A4^B@&< M>QK%*"];RM"%4>_'(\"'ZZD? )G&D=L/!>87L";16^I%H 7>W^> ,4+Y/EX, MQI?&H0+Z_''0!D6&L[ E!.)Z FI:["/WW''*I=B9LY&2"BH*NG8UD1RTPPW3&,9;_T^.;X5_CF $7 >"WN!N(0YL ME#]''!FFGH-=47 MBO7,!\'T+&N:%8_%:):8E#T)/I?1N[+0[0@M# M@$^$NA4W9X, N&@$05; 51]R82K#=%/I&8CGAF&NN;DOOT/RG-\!::7PC$!= MAC>A)R&L1SYS8F5%J^[SQJ;X@+P3\H/2LGS9??$JT@?6R>D997'$XXE?$B,9HG7J,'E\]"]1Q6CB3U!Y%8355F->5>ZR:^W0V^ M_Z\?>Q]VCQ)O@)[E+O>A';L0.KJ[=M<^.'#L74P9[A_L[?? J6@[\$UW5Z18 M#[_]@7Y&N^LXF&7=6C445PH0N<@V2.17$ ([W/E'$:JZTT^J6&$0I(E:-SS0:CYAFLF>SA)''X M-VA!B*U8DCM<1P3S,'EH4(KD@M]R$;SFX7DJQ?\?)7Y@)C%@D'B#-..^"D#\ ML8>4&G)!7C_N6P 'E@S_T0L0X^OA93V\;/FK[):4[28D;'#JZSA.A9.8K*C? M.XA6?CPXF*?&']NM?08M#Q$,']$=Z>O9J ?RC6XL=@,^80)HAVSD^A H!B*, M0>>8?Q]Q<*@AXK_\[6=W.'IW].91M4) SWYT)@K,4XHR) $5@W;M0KO@+N ONC1"'#[8CJ:'>8<@$98'#F)RH_BL,X.,A2TF$!=F,N WUF,B;]^&@./>CSR>-&(/.R\ Q^6[\37U_@L M-318.AZ-0O1L Y5=Q"Z+1 &,!#$)DYQ[&'X.F!;&_ M9D/X0"C)M32"M^WT$^Y^VW&O MH1]OW?#.O4_?R44OF-L&L;Q0JQM7X\/9ZTV^?8:BYD[X;[Q1"*Q:-&2OU=6B M'=/C4XLFV2U[7XN&3".5%DW:PR5J&K3C29"M1XNU:,5YP5,X5RNI"O,>$Z;2 MHIG+HPT]VB@\C+8>QJ4)7JE!J8=,\EC 3>>& GDD,-]_I.5I+YY-PJ8"M)Q^ M/+LZ.5K%78_XC ^1QG8P,Y5R;R6L,XR8+_RB]4S&P5RT\P0Q(/ MRU^4+L%?6.9^GWRW.%5S@S/MX@VXYFLO19>W M\)4YQ$+NDT6F2@.I8*5QFLKIZPPC MK8C?B90#7 %]&8F_0<^<;7W.GW.!6O>"4&HAW0+=A/'=AE-+Y0&TD9F4#9'.(K[[T6ZU']#<(B52-OW9$*NE^WUHNDFCZ2:#K?$IFDJW-0@N(50*1L:J?5L6=FLDH#:+6L*%G@JZ8VEEK;)&_1*WL,BY(;H/"'V8V%;A\Y M[*^PX45N?46OP4WEFASQ#R206PBAHBS-A^($$5SQW10/;EH9!N<=B@3/).WP M226*R.!?;/ __V ?M-\-W+24]\RW\$PR<^4T'J[:]]"O<]%O$HCU>^NRQ82. M1.X3-Q?AL)CD^, 1#Y9N'E<.T>(]Y!+A%-;B%[/XB_P'#Q'MQ(85R42QKR?? MP"8\.+$G:J97^QQ\/-S&BKO04GX]#L5VK<@-[W'GH/!>P8E,Q=Y8 MW :,>T]QO\ZU@&/9%['YXC_;@@WX >U4:V=1L;%Y(L<6^S21Z1A]^-E4>RKW.PGNRS=9YW4(1+O*K1 ! +(B MW(,Y=X!EI8S);CZQZ4ZZ\#%N/?(&N*GZT4?#N,&]RV$(P0+FO=-,QHQ9@(*< MZD=A&\*J,J&/99GL:QJ5QB1W WB? 3#J (D@2"C:,6VFV\1EV8UN0TWB(=(F&Z@"38XH3#FU(T@93+#9( 0^-(['9/QODL13H0^\[C*!3;U_)F M3 8^7#4S(HI-@],FH@9J:?2ZZ<0_D"TKD*]5WA0%EA>/T>-.IY'"@SX!G(3W MQ9@7VSGSQ\\\TL+WW?$PQ+_QNBGPBN:)+X]>DZFY$,2!.SE(T5Z5F>08!.T: MRBH&V+")9*9VFK9FIU>*9TYC?]&J.<*;FEM3(3&J4$A=3 MAT*RV"L[,^6@7 MITS5E,(WB"([+ZJ;M&;.=\3.M?55EIII?EF$+UKDN*$VUMRC.RMP!L=9 4!^ MJ62'! :91IN,VCFDM0!%)$RF7+J,^4B7G^8\16;J J AG Z1U40$\A7IL07O MMQ229++M<(] -F 0 (F0/[QCR@DKUQ:9 F7)7&GA+\KB)Z(-CV5GX%HW=S=% MW1>1=5X^Z[_";+]R)6V^H&[.^G(G);5:,6 ;L!>DZCXJ!^/,_:P]IA1 MXJPH!U0NX]:2JX2F*TI-BD!A%!#?1:D8VV$($#?&Z"DW]=*L!7B=KG^+\8:/ MPQ0$F; 0!FBBABG$+ADV4@186(1$>4A3Q:INW=0;HY\=#(<0(N]@LUSI3EV' M+E:-P.$+PPY])H"_LRR=?IF*NA%'=_ E7KY%/Q5]1F_PAHL8 3Q5GJBB*ECG M!9IR+W<=CK,,S"?&7"*&O2BM!M^]SJ;&[./%3F1@ X% %*(;N?5$#3WV%)7EF MOY-Q_NRWZ$)YI2)ZZFM9C6GF2U!NX 4C:.*#G[QYSY:IM@?79N@(90_>F,1_ MSFL)=IT/$>P?OC5/+CWH%(R/X;P;5-VHA]_G=:-*Y3Y+[\?5_C.%0(LYI]S) M5[I!6Y ELZ82/')F'D>"\(]5O3\LD14M,3&IG#SOD->NLE3:#IXI)*QJ<2VQ M]'Q1Z/105&M!+/#^)R610FBV)&"K_ 35UGPMZHI5B:R5AL]LZG3./6X?DX+W M>;DGGMSRH@RDK&LF:AS*\E.3]&8\PMS3.();6_,>6Y:O>(XPJ.MT>N4M9I!= MS NG1+6@. MKW*AX5[^!G1*XZD:>H55I 6YO(,&JA9"\"#"3LRB@HV%8"#";?4X1SLI":Z/ M(PL *!N+)?$J/UYZD35WI,RMF7H=ETNJ2G%86/MO4O3,MPK,24O7H_<<13%: M5^Y,E@J16&^O 8?# ?T?T0L MHNK/HIWCVBU/))Y"]T[P#>#B.%2#&V].Q4R#ZL!$13*++2[%\&I2K'!NV[!# M2N\ED0VQ*II0+@9DL@)7&*29 J[(=Y%NIP?(I)YOD7U[:+YH\ ()N"_>O!($ ME2P!0[!D/,HFLX"36;12"FP:7%!:?H '4Z2E&;\)OV6*QW,L?VA/^<1H4B]"4B= !1;Q9,5M(]>-ITKJZD=:&&,G*()1V/"U;*\J$>,2=Z$R$W MRR?G+N2CI0YG<0['VG&H:Y)W)C:.D MTQ>@MAJ,L_PD^5KZD)A.CH>!9Q5:MTKC2G@>NW%2S+VB.WHM>5QT0?5AMGT3 M]R=WDU?EF>O)\E(UQPWZ4[J6;U2OY+=Q."X;BZK5C;*7U/P"P M5R;I*78NIO1GH5F$0:45%N4^3&H#BRY\^;^SDQV[QZ#!/A]B@+ '>?WL?B] MP.!5.OU."![;!(V2XWJ1]X_3]."Y9(/2+ENY(3(2I_OX>5!Z@62E7/8\,,7' M%:<(/)+DVGF8Y,H?LX P\O4L8X @7T#OK[R?C/$5>],G5ZC+R@L(Y W3Y3;+ M;B;:K"KN'V-TH7P>#-P4KPJQ^;$WEIZF+.%9K%M1G_O3Q;(G!3U/CRTU=32W M;\>*Q^5A-6@4>0G3!;5"K5*CIE83" 1?L&:H,)J2HP!7FC1CWJGIC#F5!7KT M[45F(\V3D3)^FF/HJDPKC)>9 66W=_Y91&;Y9G.Y&$^+T@=J$:46;2EAJJIA M+^$& $FD&YY0K1CW\<_=7U[4M2_3SAR%'D716)S2-:O-?Q3:%'MTI"I/((@= M]J&I'=O20Z^X%%:+AB@Z>4JE:?C_)U'MTE$TJT5'5-(3FCV42L\9TNYHU,I\ M_6\^9HII%UE(U1?9<,7B0[1M/+?BJ9E9-56$-ZR:I)T"4.&X+D[,4D&5%ZY2 MX*XX$TN<]B7=8EZLE1J-\9P2?RR6>05B D+N&UJ@C8=G.N#G.57[\92-H=C< M&(-7>S-9\.3'XMUR9@R;((]UDPF(VT#.]Z7++$*L@14R)F"I(5<9 SN*H'A>S5WB.#H0$GI2F'W.Y]!E#+9EMETM&B4(@$^>BHA0Y7DFL\!>D$#H@6E'/)/,YZF7!'TY?L7,RJ2Q:&?YJ#=K MJ59%:XLFZ\&+F"O-UZSCLCNIKKM)TK(0_Y2ODR<*993IBL5@I37LQ78,EV%K MN,Q[X.J#M'Q6#RZ O./]-(#W;N.Y&PD0H-^"A[R1A\'EK57AK=BZD%^?G]<1 M))/;=N&^J5E9>!V$JP5EB9A:'7L71V)S :ZF D81^1'<+)[(LY'DX.HGL>M; M8E6Y6-J8JC2 CR7#@WZ1DULB&HE+8J)-Q=#8,75&F9AA*" M7X%_4>1.V:\G M+?:OTGK:*:E,Z5 LHX]PQX@BSV+-;;EQ=ZC/;T7K@GQ-?AA[D_RU&(/ENR1/ MB\-X8%CF68)YAM%B7^5L^,26!-C@5$.>HI48[2L*#X8BP8=_FS7 'QX4+$8O M3K('WN,8\(3A?8+&Y.*B.*,$N/&E53.)*SDI(D:6.TF3%GDGF%?D[<14)^Z_$XBU'4GY"36#?JS 7I,_QGC">5E"^#KRVWR"S@:-X6 MZV.,X#SXQD0];J:B[M^.6+X%!_!+.4L&=.SOL7\/,!I$:[:-C72F8[=W#GKV M3M=NMPWHSI\>Z.7_A0,W0-_;@ Z][R=L=TERJ'Y32'LUG4+:4!O?NRR"V/'# MUA]'IV=??C]WT^P",[ )][]"BS]B@\4O]I8X>'&^67ABQ=]K10G3MC#'_%]Y M@]%B2AT>/SE\\GIY\O3DS\^'IT??3X^_>/R;Z>G5Y=__/[YZ/>3 MLZO3$ZE$\#9\7'7CLR??^M$-1;Y.'#*ZA%[K(;GMWR-W[./JX3>U[XK(9,3C MU,4=$AB$\%&&9R0SW)?+<:#@U;/ M^>F=ZF*N.(P:?28OE*LPLICT=AI>\ O5H/HPUF$WLW\#4O. M;NWO/5-PKR6F\L"9/@]X6E*O3!'SQ ZOAZZ"W)VM3:@@_^KC1(1**WNM]N%R MM4S.3-Z(+:^BI-[K*PF75W?LD77BFLM9N M39A[0:Q=E<&!3.1 70&)+VV MX:WB@BH$N[YB-)>7$*P_8KOK TQ!8T8)="6W8(T"=4J>/HIL+OTT#2XVJP.G M]1HZ,(XDJ]5*,WG2 #1_#GBOY4SV9N-YL]7PZI ^-1]*>M$=U'63,L4_K[5^ M2BUL1Z!DJ9HAE"Y7I*F5"94)EBD4=D:W=: M71W%>[SH\$+B06.@HBD\^"-1X(8E;MN6[1P2!9J-'@3(!,@$R+60N+UOM??V M"9 I)JEQ3'(D3VO%TC >AWBD'W*+13PC!B0&)"D3#:Y @UVB0*,-FQ"9$+F6 M4FXJ(C^Z8840F8(2G8,2K-D497$2<)H:,0B/B?6(]=98U*E#K&>T81,B$R+7 M4LI-1>3>X0%!LD&!R,M+:!D1G7Q-^,B%SDX=4RD/=\@/:W4WL>5$AW(QNIE_ MA3LXYXF>-G%6L8GS)9HPD(9MR][;VP@6M9_$##0HB 9J)&>B ?TU032PC ;: MG75/U1,-5!ZDK6^VR.FV.OLZRO(13S)Y["H6'!CA\:JT MP<:P#$-IXD-B0W7R8:] ZI!8+9M$R@3*-=2RDT%9<>R M[3:!LD$ARH9W_V@I\"]BET\8@V0RG@QIGT\S0)P6>.NB"5K@O62>9MV[;6EU M-VWR,5S.Q 'Z:X(X@#A ,[%K$XCY\;@?'MA3AF_HBI M.G;;&(4T07/[\PZ%C=]^QTW_^?G;U;[,6IE# 5V*!AO*P3DG69ZO! M0**ED\C-ES(M-R1<-U0-A.M:ZJ6QN$ZQTBNY[<>J_-UYX/:#,,B,.SNI\4%1 M ]&!UNJ;+_;&4I\!F-QPD1(J$RH;*O;&HG(] Q)=STHZ\KQX'&4I&[GW;C_D M1'_&($13Z*_B!1$-9+Z]0RKG8#AT$!H3&A,:UT+BO4.J_TE!2,V#D&3,)P>V M$NT1[9&4B?M6*BW7I2I&9MLV@3*!D.&HSO5&])%$U1O:,FVTQX=*6[LD" 2J!IZ MB 1TT021P!(2.*RP>@V10-VGC9QNJ[.OHWROXLP-F:>BLM#4C36Z6;&.M8$: M""8Z%O]I(KE:W?UUU_6A;"=-09DF4H)U'=1 L+Y +_M6ITJZH,)/(]:__0(2(W==00D52-3D0D MM5$5$U.EV*"+48-?5]\&\%:>I,5I2?\9KW\V M;L,+72H5L@[\W$"0H)W6YHN]L:M4#,#DAHN44)E0V5"Q-Q:5ZQF7Z%KKXFO" MKWF2XTV[HIHB%8KJ64"98)EBFDJ6M($>'_9YPCJV^!;^A*>,N)<%MSPT;-Y'M]%$C&R>E)O*R#;M33;; ML F1"9%K*>6F(C(=PD3149VCHR/H,%8U=T,(B0(?FL8\=Q1D;D@<: XZ$P<2 M!ZZQ%E[;MGJ] V)"HZV;8)E@N992;BHLVSV Y0Z=V6U2@$)',KGJZ-CQ9SZ\#+\AHSZOA,$XUC'31!-4P6JR:;;OG6(Z]3YM6*Q#^&R(!PZ&'2$ 7 M31 )+".![J'E=*D$3M4D8% HIGD9NW1.50.^B:H&Q,E5,P$5(ZJ-JJ@8T0MT MU[.Z/2I&9.RH(2*I&IV(2&JC*B*2ETS,=:R#+IW-J\6PJ2I"].-Q/^3,::V; M4LH2W'C5@JLO5T?G[/SLZ./9^=G5V>DE._I\PBZOOAS_XV]?SD].+RZ+"GC_ M_/WLZM_547PS]%%'@I_23',(_L=ZO#XE(0>=R?JB(]<>'NYD+ H'O_.!V@>UYT .> M/&Y\4QW^::I+5\&0I^PSOV,7\="-'H8*4PU\_69,O6K&Q!>\^<7O>;3_KQ3Y MO.\G;/>7Q7*;@@YLO.V,YD')4]6WQJ/*W^^ZLQUZ=>N;;P!__^N&=^Y]FA-!N_W472.OT\;U#H]YNIW#$,]4[<41^W1ZU[^3OD3OVP1?P9[ORK(:+=O8V0_ _ MV =M!1"2S 6U*P?HPU9[BWD\#-'% 7^I^*S\)_%9.6)24UMYQY4'!>Y+Z(Y2 M_C;_QSLV X3KS#7O@SM7X?2E%J$H"![Z!X(]V-I@P.,XK=YJZR$7!2^KCOS7 M23$_-N2>G?$?))RS3_#C(&6GT"C_%1!=[R[G]=XVDWG:R):Z*L6YT32>4S5: MZC031,A9I=U?!M^G<1-Q1;HK&P07C98*: 5"ZU\GH(/OIB4:.9M$([O=ZCBO MM+3);+S"ZK;D\M3;Y7F6>5>-0IO4 H&0WCK#8MH$0O4$(?)@"#RJ!H^->3 4 M5VGJZ9@N70(AO76V20^&0&CSR9V%0T3E>XSR@B[X+8_&/*ULV>$*D&/^JL]J M%^CV5D/^!B[KK'CA=".+<6YZ;3K52"9$-TT'A.AZZH40O::(KEVFDO"\249- M>*ZG7@C/:XKGS18I(7KE.B!$UU,OS41T@]9*ZGH RMQE(WU"+;OFS^ MSOP14%F9A6GTJFY48.K>G2;(F7"?<+^.6ND1[AN)1X3[ MA/MZJ(%P7T>MV)NIF$; 3\!OIIP)^ GXZZ@5>S/UE@GX:0W]$X3]7,D>QVF& M-?$26DNOHYW3O"[II:'SNK12I^8B)42O7 >$Z'KJA1"]IHA>J:]>N MDUX(S\W!\V:+E!"]CW3ZK1LG@RY>@QO($3;ZZXE1E9-#K=) M(B6K)2Q>D]@[:S_"EQ[ZZ[T359-6&R22,EJ"8O7)/:# M]B&9M2E)9"K((F1^R9/;P./,C7P69P.>:#"%V.R].CJ .VW8F:N:?2K-8N9P MH)V:U;OMA/[5JX'0?]D<9?> X-_(\4#P3_!/:B#X?V2)"A7H,G,\$/P3_),: M"/Z7KXK9)_BO?CP8-"/@=%N=?1V%?A5G;LB\&I5S(?+0C3S6JBH#V>6 4DMF MCA>*+?2)+8@_--83\<>+9J:=-A&(D0.&"(0(A/1$!++NV8V#=>_ )0(A C%9 MSD0@-=<3$C22/2D,/HHYZ# 2BCOKJ M;MO>HQP640?%'40>3=03D<>+R*.W3^>X5TH>]3QR0,-8X\N()VX&W67\^XA' MJ=Z;/\PW\EK00@,AOW*WBDR?ZK/63:2$Z)7K@!!=3[T0HM<4T6EF@/"<\)ST M0GAN!IXW6Z2$Z)7K@!!=3[TT$]'KF5C7]\2%,(0>6^R&1SQQ0W'T@NL/@RA( M,\R[WW(R;V,1I+&'YSC6WMKK9Y-ADR=NDDC):@F.UU7.U.KTZ#0S\)2[B3<0 MR66?W_(P'@VA<633!-:F@;5C=7J463;7L,EW)JNMGX@;#,>'SKJ/RB+#)C@V M2:1DM03'ZSH9Q%I_02PR;()CDT1*5DMPO#XX[I)W;$QF><,UT35.-V?)V,O& M"DIZ)1BM!B( B@$T%+S! M,P5.M]79UU'H5W'FABRN58EQHA#=*&2MJC*08PZM3F_=T\[$,!1DF"QGHI": MZXDHY"6Z.[ J'1.8U\,_)RBOWIX)RO74R[;=L7H' M'<)RPO*:2)/0O.DZ(#1?AN8';?+,-X7F!NTWT+4RT9=LP!,61%X\Y!:+.)4C MJEHC.H$_S:W.S*W2O*J1PX'6YNCC]Q/Z$_IKJ1K':MNT1\S,$:$# 5 2G^"? MX%];U3CK7EY#V-]<[&^"G G]]58#H?\CSC]E?ZH?$;2J_I4<_O,X3=EU$@^9 M!Q<$T1@7V*NR0W&4LCZ'1W U,\ R][O>)8@:.!1H4E@+O>#2^SV:$Z85/G61 MIC;./H$Y@;EF>MG>L[IK3_(3F!L$YI2U)R@G*-=0+V+I_1XMO2IU6C5T_HO!8X)6W^CC M]Q,%$ 7HJ1JB (/'A X40&E\(@ B 'U50P1@\)C0@0":(&>B +W50!1 %*"A MX T^!EC#8."1A?D:4,3">4GB$-TX9*VJ,I!D-K*8GSAFXPN)*,+0)\(@^M!8 M3T0?+Z*/36P?(/IH)'W0# 61A^9Z(O)X$7EL9,,"L4BA@=!?N7M%ID_[G>LF M4D+TRG5 B*ZG7@C1:XKH-$E >$YX3GHA/#<#SYLM4D+TRG5 B*ZG7IJ)Z/7, MKNM:@&BRT\"?GVS7[!" !AI\!5C?1"C?R-8R,FWRSDT2*5DM ?*ZEK+L=]9] MVF*S[=JPPLW-3GN;;ZX$P^07DVG7!HZ;+5*R6@+DM94G.*3#J4Q8RDTE\%TJ M@:^9,G3 =-K:4Z$C3EM[J/RER7(F"M!;#40!1 $:"KXI%-#L)#H10/5J( (@ M M!0\$TA@";(F2A ;S40!1 %:"AX*H%?30G\!0O3-2 )*B16&Q:A0F)$,_40 M/$4:YLB92*3F>B(2>=%2I?4OX2<&:60I8YJG(.K07$]$'11_U%'P%'^8(V"&&F3]<*DQA;8PY&NW7$G,0D!P$0<1A,'A1Q$'40=YE*'8^T=[A-UF#KAL7#D ;,EB?3<-/.9&/O.#<)QQ7Q,N:2A/Z#8U3D2@@UX:42.0*K::)E)"],IU M0(BNIUX(T6N*Z#110'A.>$YZ(3PW \^;+5)"],IU0(BNIUZ:B>CUS+7K>@[# M<2QJ+$&G]2BR9+Y!5SS/VD"4WFZWG .RZ1HOHR&/FPR60+C6$M^V6_:Z5ZDT MVZ8- ^%FI['--U>"X K\X/UUKS%OMDT;!L'D!YMNL 3"&P?A3JMCDTT;L#"; M3O(5XC[1ME#_/%W0G"&=YE*]:JC,I<%C@LI<5N^Y$P54KP:B@.6Y&+NJ_?X- M)@"JDF]ZXIR0OWHU$/*3\Z^AX,GY-T?.1 %ZJX$HX)$%B555;&DP >@P,=", M:&+*I1,1N4Z($374R^$Z#5%=/+0"<\) MSTDOA.=FX'FS14J(7KD."-'UU$LS$=WXK045"_Q?XE'<9^XM3]P;SJ+QL,\3 M%E_+308I&Z?P:Q Q+QZ.QAF(L#9;$9H]@:L3B] D[91J.HYE'S@T2VODD* U M/M4[2L0 U:N!&&"):O:L]F&/",#($:$# ="L ,$_P;^VJG$.++M#Z_O-'!(Z MX'\3Y$P,H+<:B &6I8"L_3:MTR\).9?Q0R6L?WIA-W-!(/"=']P^J;]3W?MI MJ@-7P9"G[#._8Q?QT(U*7>V-LJFFO/2%4GZ;$>#[?L)V?YEI]:+AB8VVG=&\ MX?HLP:UE(,(@=&<[M!Z]B^:7%?_7O[P?))-1?L-W^@EWO^VXUQE/WKKAG7N? MYH.XW7[J4H/7:>-[ET7N$-[WQ]'IV9??S]TTN^#PT(3[7Z'%'['!XA<'C ,D M.=\L/&@$3QZ'[7EM+D>QZXU;+USVB?N!YX;L\C[-^#"UV%GDM=AB>Z]'QS[' MT*U+[CFW_'KEC'TC+?U/[K@01RP;Q.'4C/WVS)LT\ M/O[M!^0D.5$PI/(C/FRUMYC'PQ ]!? YBL_*!Q&?E3,C6[N5]T,Y(N %A.XH MY6_S?[QC.<[9K>ZAA+K92?_"+_KXV_&7\R\7'[9^^%7\M_5*GE*GUSJLNM3X M @W-]^5!>M 8$,W!UB:DM-#3=PY;AX>K%2A=Y->O:M6:ISZO!@GG[!/\.$C9 M*;3*9W\?1YQUVM9\9U^N9%FH*RG?=NOP8$TKQYCF7 M)J*;TW8>6Q.X1@P[:""&;=QK>M$P:-A\H38(MM=J'Q*"K8A@"T[CIC#W*6$N M ?&F@)AP5A^<=9Y5^*^A.%NAITAY. V!;.%P(02C6%>_@;/84]Q0OHX0[$EY MO6'@^R%?YVI!E=@S#*[.<9OT=1(/ :2B+(C&N'\Z+C)W%98N684[S%\A6UF5 M:]M>+:O0P*6QVX?6WMZZS\Q9J)B-I4(UJEB]8>QIQO0QH7F#T-R9)<(AP:J^&2L.'UU"!B81C=ZS>WKHW M5U^O>*KT,SC>SNE4[ D?)=R3 M.RY%@51W&"=9\%_Q1;60;[Y95TRL$M8;B-IVITK$)M,F+[R&$B5(WEBFOH&0 MW%F^-KOBE=A5VT53TC958QRQ!K%&#:4LT^V-9(UUGU- D$R0;)A$"9(IM[+& MBH7[^Y0-W[!I4TK\-<5[AGM8>)JQ(/+B(2>@)J V$:BW;4J"TRJ4^@B3W.8& M2+FQ^>]M>\&>(EJ%;DHB1^<)!B(,(HQ:2KFQJ>]MNVL\8C:5D@B-"8UK*>4& M)U/6?5YNX[/>&UP#KD4Q9UVRX/S[B$=IQ6GP58I2F3\$M$#WUU"%@0SP\P^' MCNULYO16F0#2J$A8U;+?Y,&Y5)^5B*#AFG >+5+88"+8?NI"]H:BR;JS*SI7 M!*YV%H"8C)B,-#&G4 TQ694AC5XX7;7LB0B,$3,1@?Z:H-S6$MVL>Z99T]+W MNHT(6N;_FN(]_7AV=7*D!_0WN*J95KA/I+)\0[UD&GRDB"=BL0IM<* M3 C3M5 #)8<68WK;ZNU7>8P)[7FH2_;?[K2Z.@KW,HN];SM]-^5X2/<0=SE0 MU?NF@'H#,=MVJL1K,FURQ&LH48+DC67L&PC)!\Z"8ID;R\;KG"QN2N:F:HPC MUB#6J*&4&UOZQSFLLL0R03)!<@TE2I!,N94UYE:L@UZ5]=@:D0TW9T&\KBGQ M"YYFR=C+Q@GT6QP'&PQ';I ,H8$$W03=)D)WQ]IWJH1N,F[RIVLH40)E2HQ7 M5'J DN.4B2'FJ*U$B3DH.6ZN.T^@3*!<0XD2*%..I>Z5Q"A!3@GR-4OX/$Y3 MMGWC!M$;%D5WV2+*7-J[>!JA&..(,XHX92;FS:?&^/$-EHRR9$ M)D2NHY0;FU;9WNM1?94UR]C<,V5U3:#_Y@819L[A#A#0.$@'F!I72?-AD*9Q M<@]79W3>K ;*T@+ZZ4R."J=4Z;Q9.IS);#$3$>BO"3IO=EFJ58Y^4\0*?1/F^JY.-OQU_.OUQ\V/KA5_'?5MTF3Y8$3$JB_3CTGZ61YXK_ MR/]SG&;<9RL=6_OZ&EB1.E":<\&*N 6U^*-&>EOQ.O2 P4L&N$9\5 ]>6C%XWJ)A^;ST+YUV%YZI.]"7;YX,JC^TJN*.+1+ M,K["9!"1+)$LD:RF)+OBZ<1$LO-)MF=U#QWB"BV40<$>\1#Q4'UYB)*.+SAU MV;:ZW0J)B&;$ELZ([69N/^3PG1_>F\ 9[8CNC>?CS? &_=C>[[W?=7V8ZM"'[>+_;C_W[7_X* MPV>0#4/XQ_\'4$L! A0#% @ )(X/58L;1Z6P! ]A4 !$ M ( ! ')M960M,C R,C X,34N>'-D4$L! A0#% @ )(X/5?O; M9]HU!P Y$L !4 ( !WP0 ')M960M,C R,C X,35?;&%B M+GAM;%!+ 0(4 Q0 ( "2.#U5G-&WU"P4 LM 5 " M 4<, !R;65D+3(P,C(P.#$U7W!R92YX;6Q02P$"% ,4 " DC@]5M M\6,1 #MCP % @ &%$0 #DY,5\S-BYH=&U02P4& 4 !0!& 0 SE@ end